Nationa

MSN Laboratories launches posaconazole in domestic market

Our Burea Hyderabad | Updated on May 21, 2021

To treat black fungus

MSN Laboratories Pvt Ltd on Friday launched Posaconazole in the domestic market to treat black fungus. The Hyderabad-based company has launched the product under the brand name, PosaOne as 100 mg Delayed Release tablets and 300 mg injections, respectively.

Posaconazole is a triazole antifungal agent indicated for treating mucormycosis or or black fungus. Many patients recovering from Covid-19 have been detected with the rare and deadly fungal infection . With mortality rates on the incline, an anti-fungal medication is of urgent need.

Also read: MSN Labs inks pact with Eli Lilly on covid drug baricitinib

“MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units. The drug is approved by the Drug Controller General of India (DGCI) and matches the International quality standards,” the company said in a release.

Published on May 21, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.